A Randomized, Open-Label Study Comparing Levofloxacin Once-Daily 750 mg PO for 5 Days and Azithromycin Once-Daily 500 mg on Day One and Then 250 mg Days 2 Through 5 In a Microbiologic Evaluation for Emergence of Resistance in the Oropharyngeal Flora of Healthy Subjects.

Trial Profile

A Randomized, Open-Label Study Comparing Levofloxacin Once-Daily 750 mg PO for 5 Days and Azithromycin Once-Daily 500 mg on Day One and Then 250 mg Days 2 Through 5 In a Microbiologic Evaluation for Emergence of Resistance in the Oropharyngeal Flora of Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2009

At a glance

  • Drugs Azithromycin; Levofloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Anthrax; Bacterial infections; Cholera; Community-acquired pneumonia; Nosocomial pneumonia; Pertussis; Pyelonephritis; Respiratory tract infections; Sexually transmitted disorders; Sinusitis; Skin and soft tissue infections; Typhoid; Urinary tract infections
  • Focus Pharmacodynamics
  • Sponsors Janssen Pharmaceuticals
  • Most Recent Events

    • 19 Jan 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top